MiNK Therapeutics, Inc. (INKT): Cash & Equivalents
$13.36M
As of 2025-12-31
$8.81M
As of 2026-06-30
-12.0%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $13.36M | +191.9% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $4.58M | +35.9% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $3.37M | -82.9% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $19.64M | -49.5% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $38.89M | n/a | 2023-03-24, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | 2025-12-31 | $13.36M | +191.9% |
| Intensity Therapeutics, Inc. (INTS) | 2025-12-31 | $11.92M | +360.3% |
| BioAtla, Inc. (BCAB) | 2025-12-31 | $7.12M | -85.5% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $7.11M | -17.9% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $1.66M | -15.4% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $8.08M | -45.9% |
| Curis Inc (CRIS) | 2025-12-31 | $5.06M | -74.7% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $8.48M | -66.1% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $4.62M | -29.0% |
Compare INKT, INTS, BCAB, ENTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗